A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

At the beginning of 2025 I knocked on the door of Cai Lei former executive of a major listed company in Beijing When I entered the room he was par ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

Ancient viral DNA embedded in the human genome has been linked to the genetic risks of certain neurodegenerative diseases, ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Background A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS ... forms of MS where ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

For the primary analysis, 186 participants who were randomized to receive DNL343 treatment were compared to 139 participants randomized to receive placebo in this regimen (n=63) or shared from a ...